Experimental cell therapy targets rare Muscle-Weakening disease
NCT ID NCT05451212
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new cell therapy called MuSK-CAART in 7 people with a rare, severe form of myasthenia gravis (MuSK MG). The treatment uses a patient's own immune cells, modified to attack the harmful antibodies causing the disease. The main goal was to check safety and find the right dose, with the hope of achieving long-term remission.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSK MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Oregon Health & Science University (OHSU)
Portland, Oregon, 97239, United States
-
UC Davis, Department of Neurology
Sacramento, California, 95817, United States
-
UC Irvine, Department of Neurology
Orange, California, 92868, United States
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.